Ingredient review —Ginger (Zingiber officinale)
What is it?
Description
Zingiber officinale, or ginger, is a well-known herb that is used globally for it’s flavor and remedial health effects. It has been used traditionally for thousands of years in India and China and for more than 1,000 years in Europe. (136)
Containing more than 400 biological constituents, ginger has a broad spectrum of pharmacological effects including as an anti-emetic, anti-inflammatory, anti-microbial, anti-lipidemic, anti-hyperglycemic, anti-tumorigenic, anti-oxidant, and immunomodulator. (4)(8)(120)(136)
The primary constituents contributing to ginger’s wide array of biological activities, as well as its pungent aroma and flavor, are 6-gingerol and 6-shogaol. (84)(145) Gingerols are isolated from the plant’s rhizomes, whereas shogaols are produced when the rhizomes are heated or dehydrated. (145)
An exponential increase in the number of published trials was seen from 2000 to 2010, including a large number of systematic reviews and meta-analyses from 2008 onwards, indicating an increasing interest in ginger’s therapeutic benefits. (8)(91)
Main uses
Analgesic
Antiemetic for chemotherapy, pregnancy, or surgery
Anti-inflammatory and antioxidant
Cardiometabolic and anti-diabetic
Gastric motility
Menstrual regulation
Formulations
Formulation
Comparison
Foods/tea
Measures generally equivalent to 1,000 mg of dried ginger powder:
One teaspoon of fresh grated raw rhizome;
Two one-inch by ¼-inch pieces of crystalized ginger;
Four cups (eight oz/cup) of commercial ginger tea or 1/2 teaspoon of grated ginger steeped for 5-10 minutes
(26)
Ginger powders, capsules, or tablets
May contain raw rhizome powder or standardized extracts;
Many standardized extracts range between 1-5% gingerol/shogaols, though some containing 20-25% may be found. Examples of standardized extract formulations found in research include:
Eurovita extract 33 (EV.EXT 33): An ethanolic standardized extract containing 1.9% by weight of 6-, 8-, and 10-gingerol (166)
Eurovita extract 35 (EV.EXT 35): A 12-20:1 standardized extract equivalent to 1,500-2,000 mg of dry ginger (37)(168)
Eurovita extract 77 (EV.EXT 77): A mixture of extracts from ginger and Alpina galanga (blue ginger) standardized to contain >30 mg hydroxymethoxyphenyl compounds and acetoxychavicol acetate in 255 mg of mixed extract (52)
Zintoma®: Dry root powder formulated as a 10:1 ethanolic (50%) extract standardized to contain 5.38 mg (2.15%) 6-gingerol, 1.8 mg (0.72%) 8-gingerol, 4.19 mg (1.78%) 10-gingerol, and 0.92 mg (0.37%) 6-shogaol (139)
Zintona EC: Enteric-coated standardized extract containing 10 mg of 6-gingerol per 250 mg capsule (167)
Liquid extracts
Measures generally equivalent to 1,000 mg of dried ginger powder:
Two droppers (two mL) of liquid extract (26)
Dosing & administration
Analgesia and recovery from exercise
Dosing & administration
2,000 mg per day for a minimum of five days starting before and continuing after an exercise bout
Outcomes
muscular pain induced by eccentric resistance exercise and prolonged running (169)
Class of evidence
a
Dosing & administration
2,000 mg (as encapsulated raw or heated powder) per day for 11 days during eccentric exercise engagement to healthy participants
Outcomes
in muscular pain (23-25%) 24 hours after exercise, compared with placebo (20)
Class of evidence
b
Dosing & administration
2,000 mg (as standardized extract with 4.3% gingerol) 24 and 48 hours post-eccentric exercise to healthy participants
Outcomes
in muscular pain (13%) 48 hours post-exercise, while placebo group pain ratings did not change (21)
Class of evidence
c
Dosing & administration
4,000 mg (as encapsulated powder) per day for five days prior to resistance training exercise in untrained adults
Outcomes
time to recover muscular strength (improved strength at 48 hours post-exercise), compared with placebo (104)
Class of evidence
c
Asthma
General outcomes from A-level evidence
No data currently available.
Dosing & administration
20 drops (as liquid extract containing 120 mg of ginger rhizome) every eight hours for two months to Px with asthma
Outcomes
rate of wheezing, chest tightness, nocturnal cough, & need for concomitant asthmatic spray (55)
Class of evidence
b
Cardiometabolic profile and weight
Dosing & administration
Up to 2,000 mg per day to adults
Outcomes
total cholesterol (~12.26 mg/dl) & triacylglycerides (~38.42 mg/dl)
Note: LDL-C may be reduced (~4.90 mg/dl), but no effect of dose observed (135)
Class of evidence
a
Dosing & administration
> 3,000 mg per day for up to eight weeks in adults younger than the age of 50 with type II diabetes, hyperlipidemia, or who are overweight
Outcomes
SBP (6.36 mmHg) & DBP (2.12 mmHg)
Note: greater reductions in SBP and DBP observed particularly in adults younger than 50 who use more than 3,000 g per day or in individuals supplementing for less than eight weeks (56)
Class of evidence
a
Dosing & administration
2,000-3,000 mg (as powder tablets) or 200 mg (as standardized ethanolic ginger extract containing 2.35-3.53 mg of 6-shogaol) per day for 12 weeks to healthy overweight or obese women
Outcomes
Class of evidence
b
Dosing & administration
1,000 mg (as encapsulated powder) per day for ten weeks to Px on peritoneal dialysis
Class of evidence
c
Dosing & administration
1,000 mg (as encapsulated powder) three times per day for 45 days to Px with hyperlipidemia
Outcomes
TGs and total cholesterol compared to placebo (5)
Class of evidence
c
Dosing & administration
750 mg (as encapsulated powder) four times per day for six weeks to obese women with breast neoplasms
Outcomes
IL-10 and hs-CRP compared with placebo and insulin, glucose, insulin resistance, LDL-C, & TGs when combined with exercise
HDL-C & HDL-C:LDL-C ratio when combined with exercise (72)
Class of evidence
c
Cognitive function
General outcomes from A-level evidence
No data currently available.
Dosing & administration
400-800 mg (as standardized ethanolic extract containing 7.33% 6-gingerol and 1.34% 5-shogaol) per day for two months to healthy middle-aged women
Outcomes
Improved cognitive scores in domains including power, continuity, and accuracy of attention, & speed and quality of working memory (142)
Class of evidence
b
Dysmenorrhea and heavy menstrual bleeding
Dosing & administration
750-2000 mg per day for the first 3-4 days of the menstrual cycle adolescent and young women with primary dysmenorrhea
Outcomes
Class of evidence
a
Dosing & administration
250-500 mg (as encapsulated ginger powder) three times per day starting two days before and/or throughout the first three days for 1-2 cycles of the menstrual period to Px with dysmenorrhea
Outcomes
Class of evidence
b
Dosing & administration
250-300 mg (as encapsulated ginger powder) three times per day starting the day before and throughout the first 3-7 days of the menstrual period for 2-3 cycles to adolescents or adults with heavy menstrual bleeding
Outcomes
Class of evidence
b
Dosing & administration
250 mg (as Zintoma®) or 200 mg (as encapsulated ginger powder) four times per day for 2-3 days at the start of the menstrual period for two cycles to Px with primary dysmenorrhea
Outcomes
Class of evidence
c
Dysphagia
Galactagogue
General outcomes from A-level evidence
No data currently available.
Dosing & administration
500 mg (as encapsulated ginger) twice per day starting two hours after delivery for seven days post-partum to healthy mothers
Outcomes
volume of produced breast milk within first three days of use (129)
Class of evidence
b
Dosing & administration
1,000-1,200 mg (as encapsulated ginger powder or powder in liquid suspension) single administration to healthy adults or Px with functional dyspepsia
Outcomes
Class of evidence
b
Dosing & administration
1,000 mg (as encapsulated ginger powder) single administration to healthy adults in states of hyperglycemia
Outcomes
Prevents gastric dysrhythmias induced by hyperglycemia compared with placebo (49)
Class of evidence
c
Dosing & administration
120 mg (as ginger extract) added to enteral feeding three times per day to hospitalized Px with respiratory distress syndrome
Outcomes
delayed-gastric emptying, reducing the need for transpyloric feeding & ventilation, possibly reducing associated nosocomial pneumonia compared with placebo (146)
Class of evidence
c
Inflammation and oxidative stress
Dosing & administration
1,000-3,000 mg per day for 2-3 months in Px with a variety of health statuses
Outcomes
serum CRP (especially with 2,000-3000 mg/day), TNF-ɑ (especially with 1,000-2000 mg/day), IL-6, prostaglandin E2 (trend), & malondialdehyde
total anti-oxidative capacity (especially with > 1,500 mg per day) (64)
Class of evidence
a
Dosing & administration
1,000 mg (as ginger extract standardized to 5% total gingerols) twice per day for four weeks to Px at increased risk for colorectal cancer
Class of evidence
b
Dosing & administration
1,000 mg (as encapsulated ginger powder extract standardized to 5% total gingerols) twice per day for four weeks to healthy adults
Outcomes
colonic PGE2 and 5-HETE inflammatory eicosanoids (178)
Class of evidence
c
Dosing & administration
750 mg (as encapsulated ginger powder) four times per day for six weeks to Px with breast cancer
Outcomes
glutathione peroxidase (GPx) by ~14% when given alone, or GPx by ~30%, NO ~15%, & adiponectin by ~17% when given with an exercise intervention
MDA by ~23% when given with an exercise intervention (73)
Class of evidence
c
Dosing & administration
250 mg (as Zintoma®) four times per day for ten weeks to obese men
Outcomes
CRP (16)
Class of evidence
c
Dosing & administration
120 mg (as ginger extract provided during high-protein enteral feeding) three times per day for three weeks to Px with acute respiratory distress syndrome
Outcomes
IL-1, IL-6, TNF-ɑ, duration of required mechanical ventilation, & length of ICU stay
red blood cell glutathione & oxygenation (162)
Class of evidence
c
Dosing & administration
10 mg of 6-gingerol (standardized to 1.4% by weight from encapsulated ginger extract) twice per day starting three days before initiation of chemotherapy to the end of the fourth chemotherapy cycle to Px with cancer
Outcomes
superoxide dismutase (SOD) and catalase (CAT) activity, & levels of glutathione peroxidase (GPx) and total glutathione (GSH/GSSG)
malondialdehyde (MDA) and NO2−/NO3− lipid peroxidation products compared with placebo (34)
Class of evidence
c
Migraines
General outcomes from A-level evidence
No data currently available.
Dosing & administration
400 mg (as encapsulated ginger extract standardized to 5% gingerols) plus 100 mg of ketoprofen at the onset of headache to Px with episodic migraines with or without aura
Outcomes
likelihood of clinical response, improvement in pain intensity, & functional capacity in 1-2 hours post-administration compared with ketoprofen alone (100)
Class of evidence
b
Dosing & administration
250 mg (as encapsulated ginger powder) at the onset of headache to Px with migraine without aura
Outcomes
migraine severity to a similar extent to sumatriptan with fewer adverse effects (96)
Class of evidence
c
Motion sickness
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,000-2,000 mg (as encapsulated ginger powder) single administration to adults reporting seasickness or about to undergo activity that may cause motion sickness
Outcomes
Class of evidence
b
Nausea, vomiting, and fatigue related to chemotherapy
General outcomes from A-level evidence
odds of acute vomiting by 42-60%, (28)(31) acute vomiting and nausea by 40%, and combined vomiting and/or nausea by 29% overall (28)
severity of acute nausea in breast cancer therapy, (144) & odds of chemotherapy-induced fatigue by 80% (31)
Note: There is also mixed, inconsistent, or lack of support for the use of ginger in chemotherapy-related nausea and vomiting, (101) including for the likelihood of overall or delayed vomiting, the likelihood or reduced severity of acute nausea, (28)(31)(88) & the incidence of nausea and incidence or frequency of vomiting in breast cancer Px (144)
Dosing & administration
Up to 1,000 mg per day for > three days in Px with cancer undergoing chemotherapy
Outcomes
odds of acute chemotherapy-induced vomiting by 60% & fatigue by 80% (31)
Class of evidence
a
Dosing & administration
250-500 mg (as encapsulated liquid ginger extract with 8.5 mg gingerols, shogoal, zingerone) twice per day three days prior to and after the first day of chemotherapy to Px with cancer using a 5-HT3 receptor antagonist antiemetic
Outcomes
severity of acute nausea on day one of chemotherapy & anticipatory nausea compared with 5-HT3 receptor antagonist antiemetic plus placebo (140)
Class of evidence
b
Dosing & administration
250-300 mg (as ginger extract standardized to 5% gingerols or Zintoma ®) four times per day starting three days before chemotherapy until 3-4 days post-chemotherapy for three cycles to Px with various cancers using routine antiemetic therapy
Outcomes
Class of evidence
b
Dosing & administration
80 mg (as encapsulated standardized ginger extract with 32 mg gingerols and 2.24 mg shogoals) twice per day for two chemotherapy cycles (approx. two months) to Px with cancer using routine antiemetic therapy
Outcomes
Improved Functional Living Index Emesis nausea score only in females and patients with head and neck cancer compared with routine therapy plus placebo (25)
Class of evidence
b
Dosing & administration
10 mg of 6-gingerol (standardized to 1.4% by weight from encapsulated ginger extract) twice per day starting three days before initiation of the chemotherapy and for 12 weeks after to Px with solid tumors using routine antiemetic therapy
Outcomes
chemotherapy completion rate, appetite score, & QoL score compared with routine therapy plus placebo
incidence of grade 3 fatigue compared with routine therapy plus placebo (83)
Class of evidence
b
Dosing & administration
500 mg (as encapsulated ginger powder) 2-4 times per day starting up to five days prior to and up to five days after chemotherapy to Px with cancer using routine antiemetic therapy
Outcomes
Class of evidence
c
Dosing & administration
~340-800 mg (as encapsulated ginger powder and adjusted for body weight), in addition to routine antiemetic therapy, one hour before the start of chemotherapy and at three and eight hours after chemotherapy to children and young adults with bone sarcoma
Outcomes
incidence of acute moderate-severe nausea and vomiting, & delayed moderate-severe nausea and vomiting compared with routine therapy plus placebo (132)
Class of evidence
c
Dosing & administration
1,000 mg (as encapsulated ginger powder) 20 minutes prior to chemotherapy and six hours post-chemotherapy to Px with cancer using low dose cyclophosphamide and drugs causing mild emesis
Outcomes
incidence of nausea and vomiting to a similar extent to metoclopramide therapy but less efficacious than ondansetron (152)
Class of evidence
c
Nausea, vomiting, and pain related to surgery (post-operative)
General outcomes from A-level evidence
Dosing & administration
1,000-1,500 mg one hour prior to anesthetic induction to Px undergoing laparoscopic or gynecological surgeries
Outcomes
Class of evidence
a
Dosing & administration
1,000-1,500 mg (as encapsulated ginger powder) one hour before gynecological laparoscopy or major gynecological surgery
Outcomes
incidence of nausea & severity of nausea within 4-6 hours & vomiting within six hours post-operation compared with placebo
Class of evidence
b
Dosing & administration
1,000 mg (as encapsulated ginger powder) 30 minutes prior to anesthesia induction for cesarean section and two hours post-surgery, with option to continue with 1,000 mg three times per day post-cesarean section for three days
Outcomes
Class of evidence
b
Dosing & administration
1,000 mg (as encapsulated ginger) combined with ondansetron one hour prior to ambulatory surgery
Outcomes
post-operative nausea and vomiting frequency & severity within 1 to 12 hour time frame compared with ondansetron plus placebo (99)
Class of evidence
b
Dosing & administration
1,250 mg (as Zintoma®) one hour prior to laparoscopic cholecystectomy surgery
Outcomes
post-operative nausea and vomiting severity, vomiting severity and frequency alone, nausea severity alone, & need for additional post-operative antiemetics (3)
Class of evidence
c
Dosing & administration
250 mg (as Zintoma®) per day for ten days prior to coronary angioplasty
Outcomes
post-operative chest pain (57)
Class of evidence
c
Dosing & administration
500 mg (as encapsulated ginger) twice per day for ten days post-tonsillectomy in addition to routine antibiotics and acetaminophen
Outcomes
pain within one day & rate of tonsil wound healing by day seven compared with control (82)
Class of evidence
c
Dosing & administration
1,000 mg before and after anesthesia prior to abdominal hysterectomy
Outcomes
vomiting scores and nausea within first two hours post-surgery compared to dexmedetomidine (71)
Class of evidence
c
Nausea and vomiting related to antiretroviral medications
General outcomes from A-level evidence
No data currently available.
Dosing & administration
500 mg (as encapsulated powder) twice per day, 30 minutes before administration of antiretroviral dose for two weeks to Px with HIV
Outcomes
frequency of mild to severe nausea and frequency of vomiting compared with placebo (32)
Class of evidence
b
Nausea and vomiting related to pregnancy
General outcomes from A-level evidence
mild-moderate nausea (163) and vomiting (46)(107)(122)(126)(157) with similar efficacy to vitamin B6, (24)(36) however evidence is also noted to be inconsistent (105)
Note: Ginger may be associated with improved control of vomiting with fewer adverse events compared with other therapies including acupuncture, chamomile, dimenhydrinate, doxylamine/vitamin B6, quince, & metoclopramide, as assessed by a network meta-analysis (153)
Dosing & administration
1000 mg per day (250 mg every four hours) for four days minimum to women experiencing nausea and vomiting in early pregnancy
Outcomes
Class of evidence
a
Dosing & administration
500-650 mg (as encapsulated ginger powder) 2-3 times per day or 250 mg 3-4 times per day (as encapsulated ginger powder or Zintoma®) for 3-4 days to pregnant women experiencing nausea or vomiting
Outcomes
Class of evidence
b
Dosing & administration
125 mg (as EV.EXT35) four times per day for four days to pregnant women experiencing daily morning sickness
Outcomes
nausea within the first day & retching for the first two days compared with placebo (168)
Class of evidence
b
Dosing & administration
150-350 mg (as encapsulated ginger powder or ginger extract tablets) three times per day for three weeks to pregnant women experiencing nausea or vomiting
Outcomes
Class of evidence
c
Dosing & administration
250 mg (in one tbsp of ginger syrup) four times per day for two weeks to pregnant women experiencing nausea or vomiting
Outcomes
likelihood of improved nausea and reduced vomiting by day six compared with placebo (76)
Class of evidence
c
Dosing & administration
200 mg (as ginger essence capsules) three times per day for five days to women experiencing nausea or vomiting
Outcomes
nausea and vomiting compared with placebo, & with similar efficacy to metoclopramide (108)
Class of evidence
c
Dosing & administration
500 mg (as encapsulated ginger powder) twice per day for one week to pregnant women experiencing nausea or vomiting
Outcomes
nausea score with similar efficacy and therapeutic speed compared with dimenhydrinate, & number of vomiting episodes with similar efficacy to dimenhydrinate by the third day
Ginger had lower rate of adverse effects than dimenhydrinate (134)
Class of evidence
c
Dosing & administration
250 mg (as encapsulated ginger powder) four times per day for four days to women hospitalized with hyperemesis gravidarum
Outcomes
nausea severity and vomiting frequency
patients preferred treatment during ginger therapy compared with placebo (48)
Class of evidence
c
Nonalcoholic fatty liver disease (NAFLD)
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,000 mg (as encapsulated ginger) twice per day for 12 weeks to Px with NAFLD
Outcomes
alanine aminotransferase (ALT), γ-glutamyl transferase (GGT), TNF-α, hs-CRP, hip circumference, insulin resistance, & hepatic steatosis grade (37)
Class of evidence
c
Osteoarthritis
Dosing & administration
500-1000 mg per day for 3-12 weeks to Px with osteoarthritis
Class of evidence
a
Dosing & administration
500-750 mg (as encapsulated ginger powder) twice per day for three months to Px with knee osteoarthritis
Outcomes
serum TNF-α & IL-1β compared with placebo
Class of evidence
b
Dosing & administration
~250 mg (as EV.EXT 77 or Zintoma ®) twice per day for six weeks to Px with knee osteoporosis
Outcomes
Class of evidence
b
Dosing & administration
170 mg (as EV.EXT 33 standardized extract) three times per day for three weeks to Px with hip or knee osteoarthritis
Outcomes
pain compared with placebo, but to a lesser extent than ibuprofen (22)
Class of evidence
b
Dosing & administration
500 mg (as tablets containing 30 mg of standardized extract) per day for four weeks to Px with hip or knee osteoarthritis
Outcomes
pain to a similar extent to ibuprofen compared with placebo (53)
Class of evidence
b
Dosing & administration
250 mg (as Zintona EC) four times per day for 12 weeks to Px with knee osteoarthritis
Outcomes
pain compared with placebo (167)
Class of evidence
c
Dosing & administration
340 mg (as EV.EXT 35 standardized extract) per day for four weeks to Px with knee or hip osteoarthritis using 1000 mg of glucosamine sulfate
Outcomes
pain with similar efficacy to the glucosamine plus diclofenac group
severity of dyspepsia compared to the glucosamine plus diclofenac group
gastrin 17, PGE1, PGE2, PGF2ɑ, & PGI2 markers showing reduced inhibition of digestive function compared to the glucosamine plus diclofenac group (37)
Class of evidence
c
Dosing & administration
1,000 mg (as topical with 5% by weight standardized extract of ginger with ~11% of 6-gingerol in a nanostructured lipid carrier) applied three times per day for 12 weeks to Px with knee osteoarthritis
Outcomes
Improved pain, stiffness, physical function, and global assessment with similar efficacy to 1% diclofenac gel, but a higher percentage of Px with >50% improvement observed with ginger (7)
Class of evidence
c
Dosing & administration
5 ml (as ginger oil) self-massaged into the knee twice per week for five weeks in addition to standard treatment to Px with knee osteoarthritis
Outcomes
Improved both VAS pain and WOMAC function scores after one and five weeks compared to standard treatment alone (159)
Class of evidence
c
Premenstrual syndrome (PMS)
General outcomes from A-level evidence
No data currently available.
Dosing & administration
250 mg (as encapsulated ginger) twice per day starting one week before menstruation to three days after for three cycles to healthy women
Outcomes
total PMS, mood symptoms, & physical symptoms severity scores during each cycle (78)
Class of evidence
b
Rheumatoid arthritis
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,500 mg (as encapsulated ginger powder) per day for 12 weeks to Px with rheumatoid arthritis
Outcomes
disease activity score & T-bet and RORγt genes (which regulate T-cell and cytokine production) expression compared with placebo
FoxP3 gene (which regulates T-cell and cytokine production) expression compared with placebo (14)
Class of evidence
b
Tuberculosis
General outcomes from A-level evidence
No data currently available.
Dosing & administration
500 mg (as Zintoma®) 30 minutes prior to each dose of anti-tuberculosis medication for four weeks to Px with tuberculosis
Outcomes
incidence of anti-tuberculosis-related nausea (41)
Class of evidence
b
Dosing & administration
250 mg (as ginger extract, equal to 1,500 mg whole ginger) twice per day with anti-tuberculosis medication for one month to Px with tuberculosis
Outcomes
TNF-ɑ, ferritin, & MDA compared with anti-tuberculosis medication and placebo (NUM)
Class of evidence
c
Type II diabetes
Dosing & administration
800-1,000 mg (as encapsulated ginger powder or ginger tablets) twice per day for 10-12 weeks to adults with type II diabetes
Outcomes
FBG, HbA1C, insulin, insulin resistance, TGs, total cholesterol, LDL-C, LDL-C:HDL-C ratio, hs-CRP, PGE2, apolipoprotein B, apolipoprotein B/apolipoprotein A-I, & MDA compared with placebo
Class of evidence
b
Dosing & administration
3,000 mg (as encapsulated ginger powder) per day for 8-12 weeks to adults with type II diabetes
Outcomes
Class of evidence
b
Ulcerative colitis
General outcomes from A-level evidence
No data currently available.
Dosing & administration
1,000 mg (as encapsulated ginger powder) twice per day for 12 weeks to Px with ulcerative colitis
Outcomes
disease severity score (Simple Clinical Colitis Activity Index Questionnaire) & MDA compared with placebo
QoL score from baseline (121)
Class of evidence
c
Adverse effects
Ginger is generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA). (84) Doses up to 6,000 mg may be applied with a low risk of mild adverse effects. (18) Heartburn appears to be documented regularly across trials, with the frequency of reports ranging between 3% to 27%. (169) Low incidences of gastrointestinal distress, nausea, and diarrhea may be reported but the prevalence is generally no greater than in controls. (8)(33)(101)(120)(163)(169)
Some studies show a higher frequency of minor gastrointestinal adverse events compared to a placebo. (6)(17) Other reports include low rates of headache (2%), cardiovascular symptoms (3.5%), respiratory symptoms (3.4%), flu-like symptoms (1.7%), intense feelings of needing to urinate (25%), and bruising, flushing or rash, but rates are generally no higher than those observed in control groups. (8)(101)
Meta-analyses and systematic reviews show no greater risk of adverse effects from ginger during pregnancy to the mother or the future offspring. (155)(163) While ginger has been described to inhibit platelet aggregation in vitro, theoretically increasing the risk of bleeding, evidence for this effect in humans remains equivocal, even with concomitant blood-thinning medications such as warfarin. (65)(67)(103)
Pharmacokinetics
Absorption
- Gingerols may be extensively glucuronidated in the stomach, intestine, and liver prior to absorption into the bloodstream, contributing to low bioavailability.
- (115)
- (165)
- Free 6-, 8-, and 10-gingerol and 6-shogaol are not detectable in plasma post-oral ingestion between doses of 100 to 2,000 mg of a standardized extract (5% gingerols) in healthy Px. (176)
- Glucuronide and sulfate conjugates are rapidly found in the blood, appearing within 30 minutes post-oral ingestion, with max concentrations achieved between 45 to 120 minutes using a standardized extract (5% gingerols) in healthy Px. (176)
- 6-Gingerol and 6-shogaol were detectable with 2,000 mg of a suspension of red ginger (Z. officinale var. Rubrum), with max concentrations reached within ~30 to 40 minutes in healthy Px. (90)
Distribution
- Conjugated gingerol and shogaol are proposed to enter tissues where they are deconjugated back into their free forms to exert their pharmacological effects. (115)
- Gingerol and shogaol are widely distributed across tissues but particularly in the stomach, intestine, liver, lung, and kidney, as shown in rats. (92)(115)
- Various constituents may pass the blood-brain barrier via passive diffusion, including 6- and 8-gingerol, 6-shogaol, and zingerone. (92)(115)(150)
Metabolism
- Gingerols and shogaols may be primarily eliminated via phase II glucuronide conjugation, as shown in rats. (114)
- Free gingerol and shogaols are mainly metabolized to glucuronide conjugates at doses up to 2,000 mg of a standardized extract (5% gingerols), though one third of 6-gingerol may be sulfate conjugates at this dose in humans. (176)
- In vitro studies show an inconsistent inhibitory effect on numerous metabolic cytochromes, possibly reflecting variance in the concentration of specific constituents found in ginger products. (86)
- Many individual constituents may or may not individually inhibit numerous cytochromes, (79)(86)(93)(174) but ginger extracts containing a natural mixture of constituents have shown in vitro inhibitory activity of CYP3A4, CYP2C9, and CYP2C19. (80)(81)
- However, in vitro concentrations required to inhibit these enzymes by 50% are typically 2-4 times higher than observed ginger phenolic plasma concentrations, indicating low likelihood of clinically relevant interactions. (113)
Excretion
- Half-life of 6-, 8-, and 10-gingerol and 6-shogaol glucuronide and sulfate conjugates ranged between 1.25-2.0 hours at the 2,000 mg dose of a standardized extract (5% gingerols) in healthy Px. (176)
- Half-life of 6-gingerol and 6-shogaol were 5.5 and 2.5 hours, respectively, with 2,000 mg of a suspension of red ginger (Z. officinale var. Rubrum) in healthy Px. (90)
- Conjugates are typically non-detectable in plasma after four hours in humans. (176)
- 6-Gingerol and 6-shogaol are primarily excreted in the bile, but can also be detected in urine, as shown in rats. (15)(117)
References
- Abe, N., Hirata, A., Funato, H., Nakai, M., & Miyamura, M. (2015). Swallowing function improvement effect of ginger (Zingiber officinale). Food Science and Technology Research, 21(5), 705–714. ()
- Adib Rad, H., Basirat, Z., Bakouei, F., Moghadamnia, A. A., Khafri, S., Farhadi Kotenaei, Z., Nikpour, M., & Kazemi, S. (2018). Effect of ginger and Novafen on menstrual pain: A cross-over trial. Taiwanese Journal of Obstetrics & Gynecology, 57(6), 806–809. ()
- Albooghobeish, M., Ghomeishi, A., Adarvishi, S., Neisi, A., Mahmoodi, K., Asadi, M., Amiri, F., Khajeh Ali, N., Kouchak, M., & Arya Nasab, S. (2018). The effect of preoperative zintoma capsule on postoperative nausea and vomiting after laparoscopic cholecystectomy. Anesthesiology and Pain Medicine, 8(5), e67132. ()
- Ali, B. H., Blunden, G., Tanira, M. O., & Nemmar, A. (2008). Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research. Food and Chemical Toxicology, 46(2), 409–420. ()
- Alizadeh-Navaei, R., Roozbeh, F., Saravi, M., Pouramir, M., Jalali, F., & Moghadamnia, A. A. (2008). Investigation of the effect of ginger on the lipid levels. A double blind controlled clinical trial. Saudi Medical Journal, 29(9), 1280–1284. ()
- Altman, R. D., & Marcussen, K. C. (2001). Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis and Rheumatism, 44(11), 2531–2538. ()
- Amorndoljai, P., Taneepanichskul, S., Niempoog, S., & Nimmannit, U. (2017). A comparative of ginger extract in nanostructure lipid carrier (NLC) and 1% diclofenac gel for treatment of knee osteoarthritis (OA). Journal of the Medical Association of Thailand, 100(4), 447–456. ()
- Anh, N. H., Kim, S. J., Long, N. P., Min, J. E., Yoon, Y. C., Lee, E. G., Kim, M., Kim, T. J., Yang, Y. Y., Son, E. Y., Yoon, S. J., Diem, N. C., Kim, H. M., & Kwon, S. W. (2020). Ginger on human health: A comprehensive systematic review of 109 randomized controlled trials. Nutrients, 12(1). ()
- Apariman, S., Ratchanon, S., & Wiriyasirivej, B. (2006). Effectiveness of ginger for prevention of nausea and vomiting after gynecological laparoscopy. Journal of the Medical Association of Thailand, 89(12), 2003–2009. ()
- Arablou, T., Aryaeian, N., Valizadeh, M., Sharifi, F., Hosseini, A., & Djalali, M. (2014). The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. International Journal of Food Sciences and Nutrition, 65(4), 515–520. ()
- Araya-Quintanilla, F., Gutierrez-Espinoza, H., Munoz-Yanez, M. J., Sanchez-Montoya, U., & Lopez-Jeldes, J. (2020). Effectiveness of ginger on pain and function in knee osteoarthritis: A PRISMA systematic review and meta-Analysis. Pain Physician, 23(2), E151–E161. ()
- Arruda, A. P. N., Zhang, Y., Gomaa, H., Bergamaschi, C. de C., Guimaraes, C. C., Righesso, L. A. R., Paglia, M. D. G., Barberato-Filho, S., Lopes, L. C., Ayala Melendez, A. P., de Oliveira, L. D., Paula-Ramos, L., Johnston, B., & El Dib, R. (2019). Herbal medications for anxiety, depression, pain, nausea and vomiting related to preoperative surgical patients: A systematic review and meta-analysis of randomised controlled trials. BMJ Open, 9(5), e023729. ()
- Arslan, M., & Ozdemir, L. (2015). Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer. Clinical Journal of Oncology Nursing, 19(5), E92–E97. ()
- Aryaeian, N., Shahram, F., Mahmoudi, M., Tavakoli, H., Yousefi, B., Arablou, T., & Jafari Karegar, S. (2019). The effect of ginger supplementation on some immunity and inflammation intermediate genes expression in patients with active rheumatoid arthritis. Gene, 698, 179–185. ()
- Asami, A., Shimada, T., Mizuhara, Y., Asano, T., Takeda, S., Aburada, T., Miyamoto, K.-I., & Aburada, M. (2010). Pharmacokinetics of [6]-shogaol, a pungent ingredient of Zingiber officinale Roscoe (Part I). Journal of Natural Medicines, 64(3), 281–287. ()
- Atashak, S., Peeri, M., Azarbayjani, M. A., Stannard, S. R., & Haghighi, M. M. (2011). Obesity-related cardiovascular risk factors after long- term resistance training and ginger supplementation. Journal of Sports Science & Medicine, 10(4), 685–691. ()
- Bartels, E. M., Folmer, V. N., Bliddal, H., Altman, R. D., Juhl, C., Tarp, S., Zhang, W., & Christensen, R. (2015). Efficacy and safety of ginger in osteoarthritis patients: A meta-analysis of randomized placebo-controlled trials. Osteoarthritis and Cartilage / OARS, Osteoarthritis Research Society, 23(1), 13–21. ()
- Betz, O., Kranke, P., Geldner, G., Wulf, H., & Eberhart, L. H. J. (2005). [Is ginger a clinically relevant antiemetic? A systematic review of randomized controlled trials]. Research in Complementary and Natural Classical Medicine, 12(1), 14–23. ()
- Biswas, S. C., Dey, R., Kamliya, G. S., Bal, R., & Tripathi, S. K. (2011). A single-masked, randomized, controlled trial of ginger extract in the treatment of nausea and vomiting of pregnancy. Journal International Medical Sciences Academy, 24(4), 167–169. ()
- Black, C. D., Herring, M. P., Hurley, D. J., & O’Connor, P. J. (2010). Ginger (Zingiber officinale) reduces muscle pain caused by eccentric exercise. The Journal of Pain, 11(9), 894–903. ()
- Black, C. D., & O’Connor, P. J. (2010). Acute effects of dietary ginger on muscle pain induced by eccentric exercise. Phytotherapy Research: PTR, 24(11), 1620–1626. ()
- Bliddal, H., Rosetzsky, A., Schlichting, P., Weidner, M. S., Andersen, L. A., Ibfelt, H. H., Christensen, K., Jensen, O. N., & Barslev, J. (2000). A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage / OARS, Osteoarthritis Research Society, 8(1), 9–12. ()
- Bone, M. E., Wilkinson, D. J., Young, J. R., McNeil, J., & Charlton, S. (1990). Ginger root--a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia, 45(8), 669–671. ()
- Borrelli, F., Capasso, R., Aviello, G., Pittler, M. H., & Izzo, A. A. (2005). Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstetrics and Gynecology, 105(4), 849–856. ()
- Bossi, P., Cortinovis, D., Fatigoni, S., Cossu Rocca, M., Fabi, A., Seminara, P., Ripamonti, C., Alfieri, S., Granata, R., Bergamini, C., Agustoni, F., Bidoli, P., Nolè, F., Pessi, M. A., Macchi, F., Michellini, L., Montanaro, F., & Roila, F. (2017). A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Annals of Oncology, 28(10), 2547–2551. ()
- Bryer, E. (2005). A literature review of the effectiveness of ginger in alleviating mild-to-moderate nausea and vomiting of pregnancy. Journal of Midwifery & Women’s Health, 50(1), e1–e3. ()
- Chaiyakunapruk, N., Kitikannakorn, N., Nathisuwan, S., Leeprakobboon, K., & Leelasettagool, C. (2006). The efficacy of ginger for the prevention of postoperative nausea and vomiting: A meta-analysis. American Journal of Obstetrics and Gynecology, 194(1), 95–99. ()
- Chang, W. P., & Peng, Y. X. (2019). Does the oral administration of ginger reduce chemotherapy-induced nausea and vomiting?: a meta-analysis of 10 randomized controlled trials. Cancer Nursing, 42(6), E14–E23. ()
- Chen, C. X., Barrett, B., & Kwekkeboom, K. L. (2016). Efficacy of oral ginger (Zingiber officinale) for dysmenorrhea: A systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine, 2016, 6295737. ()
- Chittumma, P., Kaewkiattikun, K., & Wiriyasiriwach, B. (2007). Comparison of the effectiveness of ginger and vitamin B6 for treatment of nausea and vomiting in early pregnancy: A randomized double-blind controlled trial. Journal of the Medical Association of Thailand, 90(1), 15–20. ()
- Crichton, M., Marshall, S., Marx, W., McCarthy, A. L., & Isenring, E. (2019). Efficacy of ginger (Zingiber officinale) in ameliorating chemotherapy-induced nausea and vomiting and chemotherapy-related outcomes: A systematic review update and meta-analysis. Journal of the Academy of Nutrition and Dietetics, 119(12), 2055–2068. ()
- Dabaghzadeh, F., Khalili, H., Dashti-Khavidaki, S., Abbasian, L., & Moeinifard, A. (2014). Ginger for prevention of antiretroviral-induced nausea and vomiting: A randomized clinical trial. Expert Opinion on Drug Safety, 13(7), 859–866. ()
- Daily, J. W., Zhang, X., Kim, D. S., & Park, S. (2015). Efficacy of Ginger for alleviating the symptoms of primary dysmenorrhea: A systematic review and meta-analysis of randomized clinical trials. Pain Medicine, 16(12), 2243–2255. ()
- Danwilai, K., Konmun, J., Sripanidkulchai, B.-O., & Subongkot, S. (2017). Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: A pilot study. Cancer Management and Research, 9, 11–18. ()
- Del Grossi Moura, M., Lopes, L. C., Biavatti, M. W., Kennedy, S. A., de Oliveira E Silva, M. C., Silva, M. T., & de Cássia Bergamaschi, C. (2017). Oral herbal medicines marketed in Brazil for the treatment of osteoarthritis: A systematic review and meta-analysis. Phytotherapy Research, 31(11), 1676–1685. ()
- Ding, M., Leach, M., & Bradley, H. (2013). The effectiveness and safety of ginger for pregnancy-induced nausea and vomiting: A systematic review. Women and Birth: Journal of the Australian College of Midwives, 26(1), e26–e30. ()
- Drozdov, V. N., Kim, V. A., Tkachenko, E. V., & Varvanina, G. G. (2012). Influence of a specific ginger combination on gastropathy conditions in patients with osteoarthritis of the knee or hip. Journal of Alternative and Complementary Medicine, 18(6), 583–588. ()
- Ebrahimzadeh Attari, V., Asghari Jafarabadi, M., Zemestani, M., & Ostadrahimi, A. (2015). Effect of Zingiber officinale supplementation on obesity management with respect to the uncoupling protein 1 -3826A>G and ß3-adrenergic receptor Trp64Arg polymorphism. Phytotherapy Research, 29(7), 1032–1039. ()
- Ebrahimzadeh Attari, V., Malek Mahdavi, A., Javadivala, Z., Mahluji, S., Zununi Vahed, S., & Ostadrahimi, A. (2018). A systematic review of the anti-obesity and weight lowering effect of ginger (Zingiber officinale Roscoe) and its mechanisms of action. Phytotherapy Research, 32(4), 577–585. ()
- Ebrahimzadeh Attari, V., Ostadrahimi, A., Asghari Jafarabadi, M., Mehralizadeh, S., & Mahluji, S. (2016). Changes of serum adipocytokines and body weight following Zingiber officinale supplementation in obese women: A RCT. European Journal of Nutrition, 55(6), 2129–2136. ()
- Emrani, Z., Shojaei, E., & Khalili, H. (2016). Ginger for prevention of antituberculosis-induced gastrointestinal adverse reactions including hepatotoxicity: A randomized pilot clinical trial. Phytotherapy Research, 30(6), 1003–1009. ()
- Ensiyeh, J., & Sakineh, M.-A. C. (2009). Comparing ginger and vitamin B6 for the treatment of nausea and vomiting in pregnancy: A randomised controlled trial. Midwifery, 25(6), 649–653. ()
- Ernst, E., & Pittler, M. H. (2000). Efficacy of ginger for nausea and vomiting: A systematic review of randomized clinical trials. British Journal of Anaesthesia, 84(3), 367–371. ()
- Eshaghian, R., Mazaheri, M., Ghanadian, M., Rouholamin, S., Feizi, A., & Babaeian, M. (2019). The effect of frankincense (Boswellia serrata, oleoresin) and ginger (Zingiber officinale, rhizoma) on heavy menstrual bleeding: A randomized, placebo-controlled, clinical trial. Complementary Therapies in Medicine, 42, 42–47. ()
- Fakhri, Z., Bidar, S. S., Firoozi, S., & Djafarian, K. (2018). The effects of ginger supplementation on lipid profile: A meta- analysis of randomized clinical trials. Herbal Medicines Journal, 3(3), 120–131. ()
- Festin, M. (2014). Nausea and vomiting in early pregnancy. BMJ Clinical Evidence, 2014, 1405. ()
- Firouzbakht, M., Nikpour, M., Jamali, B., & Omidvar, S. (2014). Comparison of ginger with vitamin B6 in relieving nausea and vomiting during pregnancy. Ayu, 35(3), 289–293. ()
- Fischer-Rasmussen, W., Kjaer, S. K., Dahl, C., & Asping, U. (1991). Ginger treatment of hyperemesis gravidarum. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 38(1), 19–24. ()
- Gonlachanvit, S., Chen, Y. H., Hasler, W. L., Sun, W. M., & Owyang, C. (2003). Ginger reduces hyperglycemia-evoked gastric dysrhythmias in healthy humans: possible role of endogenous prostaglandins. The Journal of Pharmacology and Experimental Therapeutics, 307(3), 1098–1103. ()
- Grøntved, A., Brask, T., Kambskard, J., & Hentzer, E. (1988). Ginger root against seasickness. A controlled trial on the open sea. Acta Oto-Laryngologica, 105(1-2), 45–49. ()
- Grøntved, A., & Hentzer, E. (1986). Vertigo-reducing effect of ginger root. A controlled clinical study. Journal for Oto-Rhino-Laryngology and Its Related Specialties, 48(5), 282–286. ()
- Grzanna, R., Lindmark, L., & Frondoza, C. G. (2005). Ginger--an herbal medicinal product with broad anti-inflammatory actions. Journal of Medicinal Food, 8(2), 125–132. ()
- Haghighi, M., Khalvat, A., Toliat, T., & MSc, S. J. (2005). Comparing the effects of ginger (Zingiber officinale) extract and ibuprofen on patients with osteoarthritis. Archives of Iranian Medicine, 8(4). ()
- Haji Seid Javadi, E., Salehi, F., & Mashrabi, O. (2013). Comparing the effectiveness of vitamin b6 and ginger in treatment of pregnancy-induced nausea and vomiting. Obstetrics and Gynecology International, 2013, 927834. ()
- Hamid, R., Ganji, F., & Nasri, H. (2006). Effects of Ginger on the Improvement of Asthma [The Evaluation of Its` Treatment Effects]. Pakistan Journal of Nutrition, 5(4). ()
- Hasani, H., Arab, A., Hadi, A., Pourmasoumi, M., Ghavami, A., & Miraghajani, M. (2019). Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials. Phytotherapy Research, 33(6), 1639–1647. ()
- asanvand, A., Ebrahimi, Y., & Mohamadi, A. (2019). The Zingiber officinale Roscoe reduces chest pain on patients undergoing coronary angioplasty: A clinical trial. Journal of Herbmed Pharmacology, 8(1), 47–50. ()
- Hewitt, V., & Watts, R. (2009). The effectiveness of non-invasive complementary therapies in reducing postoperative nausea and vomiting following abdominal laparoscopic surgery in women: A systematic review. JBI Library of Systematic Reviews, 7(19), 850–907. ()
- Hirata, A., Funato, H., Nakai, M., Iizuka, M., Abe, N., Yagi, Y., Shiraishi, H., Jobu, K., Yokota, J., Hirose, K., Hyodo, M., & Miyamura, M. (2016). Ginger orally disintegrating tablets to improve swallowing in older people. Biological & Pharmaceutical Bulletin, 39(7), 1107–1111. ()
- Hu, M.-L., Rayner, C. K., Wu, K.-L., Chuah, S.-K., Tai, W.-C., Chou, Y.-P., Chiu, Y.-C., Chiu, K.-W., & Hu, T.-H. (2011). Effect of ginger on gastric motility and symptoms of functional dyspepsia. World Journal of Gastroenterology, 17(1), 105–110. ()
- Huang, F.-Y., Deng, T., Meng, L.-X., & Ma, X.-L. (2019). Dietary ginger as a traditional therapy for blood sugar control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Medicine, 98(13), e15054. ()
- Imani, H., Tabibi, H., Najafi, I., Atabak, S., Hedayati, M., & Rahmani, L. (2015). Effects of ginger on serum glucose, advanced glycation end products, and inflammation in peritoneal dialysis patients. Nutrition , 31(5), 703–707. ()
- Jafarnejad, S., Keshavarz, S. A., Mahbubi, S., Saremi, S., Arab, A., Abbasi, S., & Djafarian, K. (2017). Effect of ginger (Zingiber officinale) on blood glucose and lipid concentrations in diabetic and hyperlipidemic subjects: A meta-analysis of randomized controlled trials. Journal of Functional Foods, 29, 127–134. ()
- Jalali, M., Mahmoodi, M., Moosavian, S. P., Jalali, R., Ferns, G., Mosallanezhad, A., Imanieh, M. H., & Mosallanezhad, Z. (2020). The effects of ginger supplementation on markers of inflammatory and oxidative stress: A systematic review and meta-analysis of clinical trials. Phytotherapy Research: PTR, 34(8), 1723–1733. ()
- Janssen, P. L., Meyboom, S., van Staveren, W. A., de Vegt, F., & Katan, M. B. (1996). Consumption of ginger (Zingiber officinale roscoe) does not affect ex vivo platelet thromboxane production in humans. European Journal of Clinical Nutrition, 50(11), 772–774. ()
- Jenabi, E. (2013). The effect of ginger for relieving of primary dysmenorrhoea. Journal of the Pakistan Medical Association, 63(1), 8–10. ()
- Jiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., & McLachlan, A. J. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology, 59(4), 425–432. ()
- Jiang, Y., Turgeon, D. K., Wright, B. D., Sidahmed, E., Ruffin, M. T., Brenner, D. E., Sen, A., & Zick, S. M. (2013). Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer. European Journal of Cancer Prevention, 22(5), 455–460. ()
- Jolad, S. D., Lantz, R. C., Chen, G. J., Bates, R. B., & Timmermann, B. N. (2005). Commercially processed dry ginger (Zingiber officinale): Composition and effects on LPS-stimulated PGE2 production. Phytochemistry, 66(13), 1614–1635. ()
- Kalava, A., Darji, S. J., Kalstein, A., Yarmush, J. M., SchianodiCola, J., & Weinberg, J. (2013). Efficacy of ginger on intraoperative and postoperative nausea and vomiting in elective cesarean section patients. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 169(2), 184–188. ()
- Kamali, A., Beigi, S., Shokrpour, M., & Pazuki, S. (2020). The efficacy of ginger and doxedetomidine in reducing postoperative nausea and vomiting in patients undergoing abdominal hysterectomy. Alternative Therapies in Health and Medicine, 26(2), 28–33. ()
- Karimi, N., Dabidi Roshan, V., & Fathi Bayatiyani, Z. (2015). Individually and combined water-based exercise with ginger supplement, on systemic inflammation and metabolic syndrome indices, among the obese women with breast neoplasms. Iranian Journal of Cancer Prevention, 8(6), e3856. ()
- Karimi, N., & Roshan, V. D. (2013). Change in adiponectin and oxidative stress after modifiable lifestyle interventions in breast cancer cases. Asian Pacific Journal of Cancer Prevention, 14(5), 2845–2850. ()
- Kashefi, F., Khajehei, M., Alavinia, M., Golmakani, E., & Asili, J. (2015). Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: A placebo-controlled, randomized clinical trial. Phytotherapy Research, 29(1), 114–119. ()
- Kashefi, F., Khajehei, M., Tabatabaeichehr, M., Alavinia, M., & Asili, J. (2014). Comparison of the effect of ginger and zinc sulfate on primary dysmenorrhea: A placebo-controlled randomized trial. Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses, 15(4), 826–833. ()
- Keating, A., & Chez, R. A. (2002). Ginger syrup as an antiemetic in early pregnancy. Alternative Therapies in Health and Medicine, 8(5), 89–91. ()
- Khandouzi, N., Shidfar, F., Rajab, A., Rahideh, T., Hosseini, P., & Mir Taheri, M. (2015). The effects of ginger on fasting blood sugar, hemoglobin a1c, apolipoprotein B, apolipoprotein a-I and malondialdehyde in type 2 diabetic patients. Iranian Journal of Pharmaceutical Research : IJPR, 14(1), 131–140. ()
- Khayat, S., Kheirkhah, M., Behboodi Moghadam, Z., Fanaei, H., Kasaeian, A., & Javadimehr, M. (2014). Effect of treatment with ginger on the severity of premenstrual syndrome symptoms. ISRN Obstetrics and Gynecology, 2014, 792708. ()
- Kim, H. J., Kim, I. S., Rehman, S. U., Ha, S. K., Nakamura, K., & Yoo, H. H. (2017). Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism. Bioorganic & Medicinal Chemistry Letters, 27(8), 1826–1830. ()
- Kim, I. S., Kim, S. Y., & Yoo, H. H. (2012). Effects of an aqueous-ethanolic extract of ginger on cytochrome P450 enzyme-mediated drug metabolism. Die Pharmazie, 67(12), 1007–1009. ()
- Kimura, Y., Ito, H., & Hatano, T. (2010). Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biological & Pharmaceutical Bulletin, 33(12), 1977–1982. ()
- Koçak, İ., Yücepur, C., & Gökler, O. (2018). Is ginger effective in reducing post-tonsillectomy morbidity? A prospective randomised clinical trial. Clinical and Experimental Otorhinolaryngology, 11(1), 65–70. ()
- Konmun, J., Danwilai, K., Ngamphaiboon, N., Sripanidkulchai, B., Sookprasert, A., & Subongkot, S. (2017). A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Medical Oncology, 34(4), 69. ()
- Kubra, I. R., & Rao, L. J. M. (2012). An impression on current developments in the technology, chemistry, and biological activities of ginger (Zingiber officinale Roscoe). Critical Reviews in Food Science and Nutrition, 52(8), 651–688. ()
- Kulkarni, R. A., & Deshpande, A. R. (2016). Anti-inflammatory and antioxidant effect of ginger in tuberculosis. Journal of Complementary & Integrative Medicine, 13(2), 201–206. ()
- Langhammer, A. J., & Nilsen, O. G. (2014). In vitro inhibition of human CYP1A2, CYP2D6, and CYP3A4 by six herbs commonly used in pregnancy. Phytotherapy Research: PTR, 28(4), 603–610. ()
- Leach, M. J., & Kumar, S. (2008). The clinical effectiveness of Ginger (Zingiber officinale) in adults with osteoarthritis. International Journal of Evidence-Based Healthcare, 6(3), 311–320. ()
- Lee, J., & Oh, H. (2013). Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Oncology Nursing Forum, 40(2), 163–170. ()
- Lee, J. S., Kim, B., Kim, J. H., Jeong, M., Lim, S., & Byun, S. (2019). Effect of differential thermal drying conditions on the immunomodulatory function of ginger. Journal of Microbiology and Biotechnology, 29(7), 1053–1060. ()
- Levita, J., Syafitri, D. M., Supu, R. D., Mutakin, M., Megantara, S., Febrianti, M., & Diantini, A. (2018). Pharmacokinetics of 10-gingerol and 6-shogaol in the plasma of healthy subjects treated with red ginger (Zingiber officinale var. Rubrum) suspension. Biomedical Reports, 9(6), 474–482. ()
- Li, H., Liu, Y., Luo, D., Ma, Y., Zhang, J., Li, M., Yao, L., Shi, X., Liu, X., & Yang, K. (2019). Ginger for health care: An overview of systematic reviews. Complementary Therapies in Medicine, 45, 114–123. ()
- Li, L.-L., Cui, Y., Guo, X.-H., Ma, K., Tian, P., Feng, J., & Wang, J.-M. (2019). Pharmacokinetics and tissue distribution of gingerols and shogaols from ginger (Zingiber officinale Rosc.) in rats by UPLC−Q-Exactive−HRMS. Molecules, 24(3). ()
- Li, M., Chen, P.-Z., Yue, Q.-X., Li, J.-Q., Chu, R.-A., Zhang, W., & Wang, H. (2013). Pungent ginger components modulates human cytochrome P450 enzymes in vitro. Acta Pharmacologica Sinica, 34(9), 1237–1242. ()
- Lien, H.-C., Sun, W. M., Chen, Y.-H., Kim, H., Hasler, W., & Owyang, C. (2003). Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. American Journal of Physiology. Gastrointestinal and Liver Physiology, 284(3), G481–G489. ()
- Lohsiriwat, S., Rukkiat, M., Chaikomin, R., & Leelakusolvong, S. (2010). Effect of ginger on lower esophageal sphincter pressure. Journal of the Medical Association of Thailand, 93(3), 366–372. ()
- Maghbooli, M., Golipour, F., Moghimi Esfandabadi, A., & Yousefi, M. (2014). Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytotherapy Research, 28(3), 412–415. ()
- Mahluji, S., Attari, V. E., Mobasseri, M., Payahoo, L., Ostadrahimi, A., & Golzari, S. E. J. (2013). Effects of ginger (Zingiber officinale) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients. International Journal of Food Sciences and Nutrition, 64(6), 682–686. ()
- Makhdoomi Arzati, M., Mohammadzadeh Honarvar, N., Saedisomeolia, A., Anvari, S., Effatpanah, M., Makhdoomi Arzati, R., Yekaninejad, M. S., Hashemi, R., & Djalali, M. (2017). The effects of ginger on fasting blood sugar, hemoglobin a1c, and lipid profiles in patients with type 2 diabetes. International Journal of Endocrinology and Metabolism, 15(4), e57927. ()
- Mandal, P., Das, A., Majumdar, S., Bhattacharyya, T., Mitra, T., & Kundu, R. (2014). The efficacy of ginger added to ondansetron for preventing postoperative nausea and vomiting in ambulatory surgery. Pharmacognosy Research, 6(1), 52–57. ()
- Martins, L. B., Rodrigues, A. M. D. S., Rodrigues, D. F., Dos Santos, L. C., Teixeira, A. L., & Ferreira, A. V. M. (2019). Double-blind placebo-controlled randomized clinical trial of ginger ( Zingiber officinale Rosc.) addition in migraine acute treatment. Cephalalgia: An International Journal of Headache, 39(1), 68–76. ()
- Marx, W. M., Teleni, L., McCarthy, A. L., Vitetta, L., McKavanagh, D., Thomson, D., & Isenring, E. (2013). Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: A systematic literature review. Nutrition Reviews, 71(4), 245–254. ()
- Marx, W., McCarthy, A. L., Ried, K., McKavanagh, D., Vitetta, L., Sali, A., Lohning, A., & Isenring, E. (2017). The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: A double blind, randomized, placebo controlled trial. Nutrients, 9(8). ()
- Marx, W., McKavanagh, D., McCarthy, A. L., Bird, R., Ried, K., Chan, A., & Isenring, L. (2015). The effect of ginger (zingiber officinale) on platelet aggregation: A systematic literature review. PloS One, 10(10), e0141119. ()
- Matsumura, M. D., Zavorsky, G. S., & Smoliga, J. M. (2015). The effects of pre-exercise ginger supplementation on muscle damage and delayed onset muscle soreness. Phytotherapy Research, 29(6), 887–893. ()
- Matthews, A., Haas, D. M., O’Mathúna, D. P., & Dowswell, T. (2015). Interventions for nausea and vomiting in early pregnancy. Cochrane Database of Systematic Reviews, 9, CD007575. ()
- Mazidi, M., Gao, H.-K., Rezaie, P., & Ferns, G. A. (2016). The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: A systematic review and meta-analysis. Food & Nutrition Research, 60, 32613. ()
- McParlin, C., O’Donnell, A., Robson, S. C., Beyer, F., Moloney, E., Bryant, A., Bradley, J., Muirhead, C. R., Nelson-Piercy, C., Newbury-Birch, D., Norman, J., Shaw, C., Simpson, E., Swallow, B., Yates, L., & Vale, L. (2016). Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: A systematic review. JAMA: The Journal of the American Medical Association, 316(13), 1392–1401. ()
- Mohammadbeigi, R., Shahgeibi, S., Soufizadeh, N., Rezaiie, M., & Farhadifar, F. (2011). Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea. Pakistan Journal of Biological Sciences, 14(16), 817–820. ()
- Morvaridzadeh, M., Fazelian, S., Agah, S., Khazdouz, M., Rahimlou, M., Agh, F., Potter, E., Heshmati, S., & Heshmati, J. (2020). Effect of ginger (Zingiber officinale) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. Cytokine, 135, 155224. ()
- Mowrey, D. B., & Clayson, D. E. (1982). Motion sickness, ginger, and psychophysics. The Lancet, 1(8273), 655–657. ()
- Mozaffari-Khosravi, H., Naderi, Z., Dehghan, A., Nadjarzadeh, A., & Fallah Huseini, H. (2016). Effect of ginger supplementation on proinflammatory cytokines in older patients with osteoarthritis: Outcomes of a randomized controlled clinical trial. Journal of Nutrition in Gerontology and Geriatrics, 35(3), 209–218. ()
- Mozaffari-Khosravi, H., Talaei, B., Jalali, B.-A., Najarzadeh, A., & Mozayan, M. R. (2014). The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Complementary Therapies in Medicine, 22(1), 9–16. ()
- Mukkavilli, R., Gundala, S. R., Yang, C., Donthamsetty, S., Cantuaria, G., Jadhav, G. R., Vangala, S., Reid, M. D., & Aneja, R. (2014). Modulation of cytochrome P450 metabolism and transport across intestinal epithelial barrier by ginger biophenolics. PloS One, 9(9), e108386. ()
- Mukkavilli, R., Yang, C., Singh Tanwar, R., Ghareeb, A., Luthra, L., & Aneja, R. (2017). Absorption, metabolic stability, and pharmacokinetics of ginger phytochemicals. Molecules , 22(4). ()
- Mukkavilli, R., Yang, C., Tanwar, R. S., Saxena, R., Gundala, S. R., Zhang, Y., Ghareeb, A., Floyd, S. D., Vangala, S., Kuo, W.-W., Rida, P. C. G., & Aneja, R. (2018). Pharmacokinetic-pharmacodynamic correlations in the development of ginger extract as an anticancer agent. Scientific Reports, 8(1), 3056. ()
- Nabekura, T., Kamiyama, S., & Kitagawa, S. (2005). Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochemical and Biophysical Research Communications, 327(3), 866–870. ()
- Nakazawa, T., & Ohsawa, K. (2002). Metabolism of [6]-gingerol in rats. Life Sciences, 70(18), 2165–2175. ()
- Nanthakomon, T., & Pongrojpaw, D. (2006). The efficacy of ginger in prevention of postoperative nausea and vomiting after major gynecologic surgery. Journal of the Medical Association of Thailand, 89(4), S130–S136. ()
- Nayebifar, S., Afzalpour, M. E., Kazemi, T., Abtahi Eivary, S. H., & Mogharnasi, M. (2017). Changes in blood pressure, body composition, and Vo2max after 10 weeks of high intense interval training and ginger consumption in overweight women. Qom University of Medical Sciences Journal, 11(6), 19–27. ()
- Nikkhah Bodagh, M., Maleki, I., & Hekmatdoost, A. (2019). Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Science & Nutrition, 7(1), 96–108. ()
- Nikkhah-Bodaghi, M., Maleki, I., Agah, S., & Hekmatdoost, A. (2019). Zingiber officinale and oxidative stress in patients with ulcerative colitis: A randomized, placebo-controlled, clinical trial. Complementary Therapies in Medicine, 43,( 1–6. ()
- O’Donnell, A., McParlin, C., Robson, S. C., Beyer, F., Moloney, E., Bryant, A., Bradley, J., Muirhead, C., Nelson-Piercy, C., Newbury-Birch, D., Norman, J., Simpson, E., Swallow, B., Yates, L., & Vale, L. (2016). Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: A systematic review and economic assessment. Health Technology Assessment , 20(74), 1–268. ()
- Omidvar, S., Nasiri-Amiri, F., Bakhtiari, A., & Begum, K. (2019). Clinical trial for the management dysmenorrhea using selected spices. Complementary Therapies in Clinical Practice, 36, 34–38. ()
- Ozgoli, G., Goli, M., & Moattar, F. (2009). Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. Journal of Alternative and Complementary Medicine , 15(2), 129–132. ()
- Ozgoli, G., Goli, M., & Simbar, M. (2009). Effects of ginger capsules on pregnancy, nausea, and vomiting. Journal of Alternative and Complementary Medicine , 15(3), 243–246. ()
- Ozgoli, G., & Saei Ghare Naz, M. (2018). Effects of complementary medicine on nausea and vomiting in pregnancy: A systematic review. International Journal of Preventive Medicine, 9, 75. ()
- Panahi, Y., Saadat, A., Sahebkar, A., Hashemian, F., Taghikhani, M., & Abolhasani, E. (2012). Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: A pilot, randomized, open-label clinical trial. Integrative Cancer Therapies, 11(3), 204–211. ()
- Paramdeep, G. (2013). Efficacy and tolerability of ginger (Zingiber officinale) in patients of osteoarthritis of knee. Indian Journal of Physiology and Pharmacology, 57(2), 177–183. ()
- Paritakul, P., Ruangrongmorakot, K., Laosooksathit, W., Suksamarnwong, M., & Puapornpong, P. (2016). The effect of ginger on breast milk volume in the early postpartum period: A randomized, double-blind controlled trial. Breastfeeding Medicine: The Official Journal of the Academy of Breastfeeding Medicine, 11, 361–365. ()
- Park, S.-H., Jung, S.-J., Choi, E.-K., Ha, K.-C., Baek, H.-I., Park, Y.-K., Han, K.-H., Jeong, S.-Y., Oh, J.-H., Cha, Y.-S., Park, B.-H., & Chae, S.-W. (2020). The effects of steamed ginger ethanolic extract on weight and body fat loss: A randomized, double-blind, placebo-controlled clinical trial. Food Science and Biotechnology, 29(2), 265–273. ()
- Phillips, S., Ruggier, R., & Hutchinson, S. E. (1993). Zingiber officinale (ginger)--An antiemetic for day case surgery. Anaesthesia, 48(8), 715–717. ()
- Pillai, A. K., Sharma, K. K., Gupta, Y. K., & Bakhshi, S. (2011). Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatric Blood & Cancer, 56(2), 234–238. ()
- Pongrojpaw, D., & Chiamchanya, C. (2003). The efficacy of ginger in prevention of post-operative nausea and vomiting after outpatient gynecological laparoscopy. Journal of the Medical Association of Thailand, 86(3), 244–250. ()